Calamos Advisors
VRTX icon

Calamos Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Calamos Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-31,000
Closed -$5.14M – 722
2018
Q4 		$5.14M Buy
+31,000
New +$5.37M 0.03% 435

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Calamos Advisors's VRTX Position: Q1 2026 in Review

Calamos Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 77% in Q1 2026, buying an estimated $15.8M and bringing the position to 77,886 shares worth $34.8M. The position accounts for 0.12% of the portfolio, ranked #189.

Calamos Advisors first reported a position in VRTX in Q4 2013 and has held it in 37 quarters since. The position peaked at $49.9M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Calamos Advisors held 77,886 shares of Vertex Pharmaceuticals worth $34.8M as of Q1 2026.
  • Calamos Advisors bought 33,917 Vertex Pharmaceuticals shares in Q1 2026, an estimated $15.8M.
  • Vertex Pharmaceuticals made up 0.12% of Calamos Advisors's portfolio in Q1 2026, its #189 holding.
  • Calamos Advisors first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 37 quarters since.
  • Calamos Advisors's Vertex Pharmaceuticals position peaked at $49.9M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.